Ignite Creation Date:
2024-05-06 @ 12:44 PM
Last Modification Date:
2024-10-26 @ 1:03 PM
Study NCT ID:
NCT03838406
Status:
COMPLETED
Last Update Posted:
2021-01-27
First Post:
2019-02-07
Brief Title:
BReast CAncer GenesBRCA Expressions in Metastatic Gastric Cancer
Sponsor:
Chung-Ang University
Organization:
Chung-Ang University
Study Overview
Official Title:
A Pilot Trial of Platinum Based Chemotherapy According to BRCA Expressions as First-line Chemotherapy in Patients With Metastatic Gastric Cancer
Status:
COMPLETED
Status Verified Date:
2021-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators evaluated the incidence of BRCA loss in patients with advanced gastric cancer and observed the treatment outcome and prognosis according to BRCA loss And the investigators evaluated the possibility of BRCA loss as a predictive and prognostic factor
Detailed Description:
Stomach cancer is still the leading cause of cancer deaths globally and is reported to be the second leading cause of cancer deaths in Korea 187 Although the number of radical resection has increased due to the development of early diagnosis many patients experience recurrence after radical resection It is also diagnosed as a non - resectable disease locally advanced at the time of initial diagnosis or with a metastasis In patients with recurrent metastatic gastric cancer conventional palliative chemotherapy is the best treatment and in advanced gastric cancer combination therapy with fluoropyrimidine fluorouracil capecitabine S1 and platinum oxaliplatin cisplatin The progression-free survival was 3-5 months and overall survival of 6-10 months in metastatic gastric cancer patients
The investigators evaluated the incidence of BRCA loss in patients with advanced gastric cancer and observed the treatment outcome and prognosis according to BRCA loss And the investigators evaluated the possibility of BRCA loss as a predictive and prognostic factor
The investigators evaluated the incidence of BRCA loss in patients with advanced gastric cancer and observed the treatment outcome and prognosis according to BRCA loss And the investigators evaluated the possibility of BRCA loss as a predictive and prognostic factor
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None